Saturday 17 October 2026 Export KRMD’s income statement to Excel — free account

KORU Medical Systems, Inc.

KRMD Healthcare Medical Instruments & Supplies

KORU Medical Systems, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $41.1 million, up 22.2% from fiscal 2024. In the quarter to June 2026, revenue grew 18.2%, EPS grew 222.2%, free cash flow grew 26.2% and total debt fell 50.9%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

3.00 0.03 −0.99%

Follow KRMD

Alert me

Market cap: $139.9M
P/E: 0.0×
Fwd P/E: −89.3×
Dividend yield: —
F-score: 5/9
Altman Z: 14.46
Beneish M: −2.90
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.22

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	4	1	—	—	1	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 6.58%

Capital & Financial Ratios $m

Market Cap 139.90

Revenue 45.11

Net Income (1.82)

Free Cash Flow 0.25

Net Debt (8.22)

Current Ratio 2.72

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (89.30)

P/S ratio 3.06

P/B ratio 7.66

Past 5Y EPS Growth —

This Y EPS Growth 34.88%

Next Y EPS Growth 152.85%

Next Y revenue growth 16.78%

Next 5Y EPS Growth 41.57%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 20.27%

10-year low 10-year high

P/B against its own 10 years 71.58%

10-year low 10-year high

EV/Sales against its own 10 years 21.67%

10-year low 10-year high

EV/FCF against its own 10 years 76.81%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	11	10	9	8
Receivables	4	6	7	6
Inventory	3	3	4	5
Other	—	—	—	—
	20	19	20	20

	2023	2024	2025	Q'26
Payables	1	2	2	3
ST’ Debt	—	—	—	—
Other	1	0	0	0
	4	7	8	7

Compound Annual Growth %

	10y	5y	3y
Sales	12.88%	11.21%	13.81%
Cash Flow	(13.25%)	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	9.13%	(13.96%)	(18.36%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	12	12	—	—	—
’25	10	10	10	11	41
’24	8	8	8	9	34
’23	7	7	7	7	29
’22	6	7	8	7	28
’21	5	6	6	6	23
’20	6	8	6	4	24

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	0	0	0	1	0
’24	0	0	(1)	1	0
’23	(5)	0	(1)	1	(5)
’22	(2)	(3)	(2)	1	(5)
’21	(3)	0	(1)	(1)	(4)
’20	0	3	(2)	(2)	(1)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	(1)	0	0	1	0
’24	0	0	(2)	1	(2)
’23	(5)	0	(1)	1	(6)
’22	(3)	(4)	(3)	1	(8)
’21	(3)	0	(1)	(1)	(5)
’20	0	2	(2)	(2)	(2)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.02)	0.01	—	—	—
’25	(0.03)	0.00	—	(0.01)	(0.06)
’24	(0.04)	(0.02)	—	(0.03)	(0.13)
’23	(0.05)	(0.05)	(0.03)	(0.16)	(0.30)
’22	(0.06)	(0.07)	(0.03)	(0.04)	(0.19)
’21	(0.03)	(0.03)	(0.02)	(0.02)	(0.10)
’20	0.01	(0.03)	0.01	(0.02)	(0.03)

Fiscal quarters ending in the months shown.

value withheld pending a data check

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	0.28	0.34	0.83	1.36	3.60	2.30	1.82	2.00	1.98	1.86	Analyst estimates 2026–2028 Powerpack
	High	0.59	1.27	1.80	6.97	12.84	6.07	3.68	4.48	4.60	6.61
People
People	Employees	55	69	76	71	101	77	86	82	80	73
	Revenue/emp, $m	0.00	0.00	0.23	0.33	0.24	0.31	0.32	0.35	0.42	0.56
Income, $m
Income, $m	Revenue	12	13	17	23	24	23	28	29	34	41
	Gross margin, %	59.86	61.13	62.30	64.13	61.78	58.62	55.09	58.59	63.40	62.26
	EBT	1	1	1	1	(1)	(6)	(11)	(10)	(6)	(3)
	EBT margin, %	9.33	9.82	6.78	3.01	(4.94)	(27.09)	(38.27)	(34.27)	(18.02)	(6.36)
	Net income	1	1	1	1	(1)	(5)	(9)	(14)	(6)	(3)
	Depreciation	0	0	0	0	0	0	1	1	1	1
Per share, $
Per share, $	Revenue	0.32	0.35	0.46	0.60	0.58	0.53	0.62	0.63	0.73	0.89
	Earnings	0.02	0.02	0.02	0.01	(0.03)	(0.10)	(0.19)	(0.30)	(0.13)	(0.06)
	Cash flow	0.05	0.02	0.04	0.01	(0.02)	(0.10)	(0.12)	(0.11)	(0.01)	0.01
	Capex	0.00	(0.01)	(0.01)	(0.01)	(0.02)	(0.01)	(0.06)	(0.02)	(0.03)	(0.02)
	Free cash flow	0.05	0.02	0.03	0.00	(0.04)	(0.11)	(0.18)	(0.13)	(0.04)	(0.01)
	Book value	0.19	0.20	0.24	0.29	0.86	0.82	0.70	0.45	0.37	0.37
	Shares, m	38	38	38	39	42	44	45	46	46	46
Valuation, ×
Valuation, ×	P/E	0.00	44.35	77.46	366.85	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	1.37	3.02	3.63	10.93	10.44	5.67	5.73	3.81	5.24	6.52
	P/B	2.52	5.24	7.02	22.54	6.98	3.65	5.10	5.33	10.49	15.74
	EV/Sales	1.08	2.70	3.32	10.68	9.31	4.59	5.12	3.41	4.96	6.31
	EV/FCF	(12.88)	52.72	57.39	2,192.84	(126.56)	(23.02)	(17.39)	(17.06)	(101.02)	(532.53)
Cash, $m
Cash, $m	Operating cash flow	2	1	1	0	(1)	(4)	(5)	(5)	0	0
	Capex	0	0	0	0	(1)	0	(3)	(1)	(1)	(1)
	Free cash flow	2	1	1	0	(2)	(5)	(8)	(6)	(2)	0
Balance, $m
Balance, $m	Working capital	6	6	7	9	34	33	23	16	12	12
	Total debt	—	—	—	0	0	1	0	0	0	0
	Net debt	(4)	(4)	(5)	(6)	(27)	(25)	(17)	(11)	(9)	(9)
	Shareholders’ equity	7	8	9	11	36	37	31	20	17	17
Returns, %
Returns, %	ROA	9.33	10.37	9.19	4.62	(4.51)	(11.24)	(20.71)	(38.82)	(21.79)	(9.52)
	ROIC	0.00	22.52	19.65	6.82	(8.78)	(39.35)	(47.08)	(69.86)	(54.19)	(22.51)
	ROE	11.00	12.62	10.95	5.59	(5.12)	(12.56)	(25.54)	(53.18)	(32.64)	(15.58)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
SMTI Sanara MedTech Inc.	$322.4M	— (loss-making)	125×	+9.04% (above 0%: growing)	n/m	+131.28% (above 0%: growing)	92.96%	6.33%	Compare
OSUR OraSure Technologies, Inc.	$262.8M	— (loss-making)	— (loss-making)	−1.93% (below 0%: shrinking)	n/m	−1.40% (below 0%: shrinking)	43.46%	17.76%	Compare
UTMD Utah Medical Products, Inc.	$237.8M	22.7×	28.7×	−14.31% (below 0%: shrinking)	−10.64% (below 0%: shrinking)	−55.74% (below 0%: shrinking)	55.79%	31.06%	Compare
PDEX Pro-Dex, Inc.	$194.1M	13.8×	23.5×	+16.65% (above 0%: growing)	+143.24% (above 0%: growing)	−78.95% (below 0%: shrinking)	34.75%	17.29%	Compare
KRMD KORU Medical Systems, Inc.	$139.9M	— (loss-making)	— (loss-making)	+18.15% (above 0%: growing)	n/m	+26.17% (above 0%: growing)	65.14%	5.21%
NYXH Nyxoah SA	$121.2M	— (loss-making)	— (loss-making)	+486.62% (above 0%: growing)	n/m	+4.01% (above 0%: growing)	59.73%	(268.25%)	Compare
STXS Stereotaxis Inc.	$105.2M	— (loss-making)	— (loss-making)	−12.82% (below 0%: shrinking)	n/m	+0.45% (above 0%: growing)	58.49%	(59.56%)	Compare
MBOT Microbot Medical Inc.	$63.8M	— (loss-making)	—	+1,047.62% (above 0%: growing)	n/m	−98.72% (below 0%: shrinking)	(266.80%)	(2,567.63%)	Compare
ZTEKF Zentek Ltd.	$62.3M	— (loss-making)	—	−95.36% (below 0%: shrinking)	n/m	−254.61% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$157.6M	—	28.7×	+3.56%	—	−28.57%	49.62%	3.17%

All 55 Medical Instruments & Supplies stocks →

KORU Medical Systems, Inc. (KRMD) key facts

Strength: KORU Medical Systems, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $41.1 million, up 22.2% from fiscal 2024.
KORU Medical Systems, Inc. (KRMD) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, KRMD traded at $3.00, a market capitalization of $139.9 million.
Return on equity was −15.6% and debt-to-equity 0.00.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 14.46 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.